$266 Million is the total value of Aquilo Capital Management, LLC's 13 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 28.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $44,758,568 | +11.1% | 1,103,515 | -9.4% | 16.81% | +15.8% |
MRUS | Sell | MERUS N V | $22,154,726 | -26.6% | 1,432,109 | -5.0% | 8.32% | -23.5% |
RGNX | Sell | REGENXBIO INC | $20,359,473 | -20.4% | 897,684 | -7.2% | 7.65% | -17.0% |
QURE | Sell | UNIQURE NV | $14,165,440 | -10.3% | 624,854 | -25.7% | 5.32% | -6.5% |
GMAB | Sell | GENMAB A/Ssponsored ads | $10,291,898 | +30.8% | 242,848 | -0.8% | 3.87% | +36.3% |
FDMT | Exit | 4D MOLECULAR THERAPEUTICS IN | $0 | – | -3,573 | -100.0% | -0.01% | – |
SPRO | Exit | SPERO THERAPEUTICS INC | $0 | – | -3,403,210 | -100.0% | -2.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
UNIQURE NV | 18 | Q1 2023 | 10.8% |
SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
REGENXBIO INC | 16 | Q3 2023 | 12.6% |
BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
ARGENX SE | 15 | Q3 2023 | 3.7% |
SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
MERUS N V | 14 | Q3 2023 | 13.0% |
GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-03-18 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.